Viridian Therapeutics Inc VRDN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Viridian Therapeutics to Participate in Upcoming June Investor Conferences
-
Viridian Therapeutics Announces Pricing of Upsized Concurrent Public Offerings of 1.75% Convertible Senior Notes Due 2032 and Common Stock with Aggregate Gross Proceeds of $350.0 Million
-
Viridian Therapeutics Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2032, Common Stock and Series B Non-Voting Convertible Preferred Stock
-
Viridian Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Progress
-
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑2 Clinical Trial in Chronic Thyroid Eye Disease
-
Viridian Shares Fall After Competing Amgen Eye Drug Performs Well
-
Viridian Therapeutics Announces Positive Topline Results from Elegrobart Phase 3 REVEAL‑1 Clinical Trial in Active Thyroid Eye Disease
-
Viridian Therapeutics in Royalty Financing Deal With DRI Healthcare for Up to $300 Million
Trading Information
- Previous Close Price
- $16.14
- Day Range
- $16.18–16.68
- 52-Week Range
- $13.18–34.29
- Bid/Ask
- $16.34 / $17.00
- Shares Outstanding
- 110.43M
- Market Cap
- $1.81B
- Volume/Avg
- 1M / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 20.02
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 252
Valuation
|
Metric
|
VRDN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.21 |
Price/Sales | 20.02 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VRDN
|
|---|---|
Quick Ratio | 14.71 |
Current Ratio | 15.15 |
Interest Coverage | −48.67 |
Quick Ratio
VRDN
Profitability
|
Metric
|
VRDN
|
|---|---|
Return on Assets (Normalized) | −44.62% |
Return on Equity (Normalized) | −72.82% |
Return on Invested Capital (Normalized) | −52.92% |
Return on Assets
VRDN
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Kwjmpdmf | Llnmgvg | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Vqvdwffj | Lymmsdf | $64B | |||
| argenx SE ADR
ARGX
| Lqcsphclr | Jskb | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qzcwmqln | Bddmqw | $38B | |||
| Royalty Pharma PLC Class A
RPRX
| Xkrbjjdnf | Gcbbp | $24B | |||
| BioNTech SE ADR
BNTX
| Yvrssqpx | Mpjy | $23B | |||
| Incyte Corp
INCY
| Xnsffcl | Kqk | $22B | |||
| Moderna Inc
MRNA
| Ptwnbpmpn | Msqq | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Vlnvnpgh | Ycfcf | $14B | |||
| BridgeBio Pharma Inc
BBIO
| Sflstqz | Dbfl | $13B |
United States